Keyword Connections

•  James Crowe

Resources

• No matching connections

Communities

• No matching connections

Publications

• Intranasal influenzavirus vaccine in children.
  Edwards KM, Dupont WD
  (1998) N Engl J Med 339: 922; author reply 922-3
• Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.
  Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE
  (2008) Nature 455: 532-6
• Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.
  Joyce MG, Wheatley AK, Thomas PV, Chuang GY, Soto C, Bailer RT, Druz A, Georgiev IS, Gillespie RA, Kanekiyo M, Kong WP, Leung K, Narpala SN, Prabhakaran MS, Yang ES, Zhang B, Zhang Y, Asokan M, Boyington JC, Bylund T, Darko S, Lees CR, Ransier A, Shen CH, Wang L, Whittle JR, Wu X, Yassine HM, Santos C, Matsuoka Y, Tsybovsky Y, Baxa U, NISC Comparative Sequencing Program, Mullikin JC, Subbarao K, Douek DC, Graham BS, Koup RA, Ledgerwood JE, Roederer M, Shapiro L, Kwong PD, Mascola JR, McDermott AB
  (2016) Cell 166: 609-623
• Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.
  Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Wilson IA
  (2010) Science 328: 357-60
• Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes.
  Monsalvo AC, Batalle JP, Lopez MF, Krause JC, Klemenc J, Hernandez JZ, Maskin B, Bugna J, Rubinstein C, Aguilar L, Dalurzo L, Libster R, Savy V, Baumeister E, Aguilar L, Cabral G, Font J, Solari L, Weller KP, Johnson J, Echavarria M, Edwards KM, Chappell JD, Crowe JE, Williams JV, Melendi GA, Polack FP
  (2011) Nat Med 17: 195-9
• The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1.
  Thomas PG, Dash P, Aldridge JR, Ellebedy AH, Reynolds C, Funk AJ, Martin WJ, Lamkanfi M, Webby RJ, Boyd KL, Doherty PC, Kanneganti TD
  (2009) Immunity 30: 566-75
• Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes.
  Curotto de Lafaille MA, Muriglan S, Sunshine MJ, Lei Y, Kutchukhidze N, Furtado GC, Wensky AK, Olivares-Villagómez D, Lafaille JJ
  (2001) J Exp Med 194: 1349-59
• Viral acute lower respiratory infections impair CD8+ T cells through PD-1.
  Erickson JJ, Gilchuk P, Hastings AK, Tollefson SJ, Johnson M, Downing MB, Boyd KL, Johnson JE, Kim AS, Joyce S, Williams JV
  (2012) J Clin Invest 122: 2967-82
• Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses.
  Thornburg NJ, Nannemann DP, Blum DL, Belser JA, Tumpey TM, Deshpande S, Fritz GA, Sapparapu G, Krause JC, Lee JH, Ward AB, Lee DE, Li S, Winarski KL, Spiller BW, Meiler J, Crowe JE
  (2013) J Clin Invest 123: 4405-9
• H7N9 influenza virus neutralizing antibodies that possess few somatic mutations.
  Thornburg NJ, Zhang H, Bangaru S, Sapparapu G, Kose N, Lampley RM, Bombardi RG, Yu Y, Graham S, Branchizio A, Yoder SM, Rock MT, Creech CB, Edwards KM, Lee D, Li S, Wilson IA, García-Sastre A, Albrecht RA, Crowe JE
  (2016) J Clin Invest 126: 1482-94
• Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies.
  Zhu X, Turner HL, Lang S, McBride R, Bangaru S, Gilchuk IM, Yu W, Paulson JC, Crowe JE, Ward AB, Wilson IA
  (2019) Cell Host Microbe 26: 729-738.e4
• Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice.
  Gilchuk IM, Bangaru S, Gilchuk P, Irving RP, Kose N, Bombardi RG, Thornburg NJ, Creech CB, Edwards KM, Li S, Turner HL, Yu W, Zhu X, Wilson IA, Ward AB, Crowe JE
  (2019) Cell Host Microbe 26: 715-728.e8
• Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia.
  McAuley JL, Hornung F, Boyd KL, Smith AM, McKeon R, Bennink J, Yewdell JW, McCullers JA
  (2007) Cell Host Microbe 2: 240-9
• Interferon response and respiratory virus control are preserved in bronchial epithelial cells in asthma.
  Patel DA, You Y, Huang G, Byers DE, Kim HJ, Agapov E, Moore ML, Peebles RS, Castro M, Sumino K, Shifren A, Brody SL, Holtzman MJ
  (2014) J Allergy Clin Immunol 134: 1402-1412.e7
• Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice.
  Wanzeck K, Boyd KL, McCullers JA
  (2011) Am J Respir Crit Care Med 183: 767-73
• Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites.
  Winarski KL, Thornburg NJ, Yu Y, Sapparapu G, Crowe JE, Spiller BW
  (2015) Proc Natl Acad Sci U S A 112: 9346-51
• Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses.
  Sevy AM, Wu NC, Gilchuk IM, Parrish EH, Burger S, Yousif D, Nagel MBM, Schey KL, Wilson IA, Crowe JE, Meiler J
  (2019) Proc Natl Acad Sci U S A 116: 1597-1602
• HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection.
  Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, Mallal S, Phillips E, James I, Halloran ME, Thomas PG, Corey L
  (2013) Proc Natl Acad Sci U S A 110: 13492-7
• Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019-2020: A Test-Negative Study.
  Grijalva CG, Feldstein LR, Talbot HK, Aboodi M, Baughman AH, Brown SM, Casey JD, Erickson HL, Exline MC, Files DC, Gibbs KW, Ginde AA, Gong MN, Halasa N, Khan A, Lindsell CJ, Nwosu SK, Peltan ID, Prekker ME, Rice TW, Shapiro NI, Steingrub JS, Stubblefield WB, Tenforde MW, Patel MM, Self WH, Influenza and Other Viruses in the Acutely Ill (IVY) Network
  (2021) Clin Infect Dis 73: 1459-1468
• Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus.
  Dulek DE, Williams JV, Creech CB, Schulert AK, Frangoul HA, Domm J, Denison MR, Chappell JD
  (2010) Clin Infect Dis 50: 1493-6
• Virus glycosylation: role in virulence and immune interactions.
  Vigerust DJ, Shepherd VL
  (2007) Trends Microbiol 15: 211-8
• Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States.
  Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR, Higgs E, Randolph AG, Smoot BE, Thompson BT, NHLBI ARDS Network
  (2012) Crit Care Med 40: 1487-98
• Emergency department visits for influenza A(H1N1)pdm09, Davidson County, Tennessee, USA.
  Self WH, Grijalva CG, Zhu Y, Talbot HK, Jules A, Widmer KE, Edwards KM, Williams JV, Shay DK, Griffin MR
  (2012) Emerg Infect Dis 18: 863-5
• Unveiling the burden of influenza-associated pneumococcal pneumonia.
  Grijalva CG, Griffin MR
  (2012) J Infect Dis 205: 355-7
• Antibody Determinants of Influenza Immunity.
  Crowe JE
  (2019) J Infect Dis 219: S21-S29
• Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets.
  McCullers JA, McAuley JL, Browall S, Iverson AR, Boyd KL, Henriques Normark B
  (2010) J Infect Dis 202: 1287-95
• Influenza virus primes mice for pneumonia from Staphylococcus aureus.
  Iverson AR, Boyd KL, McAuley JL, Plano LR, Hart ME, McCullers JA
  (2011) J Infect Dis 203: 880-8
• A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.
  Edwards KM, Dupont WD, Westrich MK, Plummer WD, Palmer PS, Wright PF
  (1994) J Infect Dis 169: 68-76
• Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza.
  Karlström A, Boyd KL, English BK, McCullers JA
  (2009) J Infect Dis 199: 311-9
• Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.
  Callahan ST, Wolff M, Hill HR, Edwards KM, NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group
  (2014) J Infect Dis 210: 1270-4
• An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody.
  Krause JC, Ekiert DC, Tumpey TM, Smith PB, Wilson IA, Crowe JE
  (2011) mBio 2: e00345-10